The estimated Net Worth of William C Jr Bertrand is at least 1.57 百万$ dollars as of 16 January 2024. Mr. Bertrand owns over 23,589 units of Adaptimmune Therapeutics Plc stock worth over 21,817$ and over the last 9 years he sold ADAP stock worth over 183,298$. In addition, he makes 1,369,510$ as Chief Operating Officer at Adaptimmune Therapeutics Plc.
Sign up
Mr. Bertrand ADAP stock SEC Form 4 insiders trading
William has made over 16 trades of the Adaptimmune Therapeutics Plc stock since 2015, according to the Form 4 filled with the SEC. Most recently he sold 23,589 units of ADAP stock worth 16,512$ on 16 January 2024.
The largest trade he's ever made was buying 207,000 units of Adaptimmune Therapeutics Plc stock on 14 December 2020 worth over 142,830$. On average, William trades about 8,401 units every 84 days since 2015. As of 16 January 2024 he still owns at least 20,201 units of Adaptimmune Therapeutics Plc stock.
You can see the complete history of Mr. Bertrand stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
William Bertrand biography
William C. Bertrand Jr., Esq., J.D. serves as Chief Operating Officer of the Company. Mr. Bertrand's prior experience includes a 12 year tenure at MedImmune, where he served as its first General Counsel and Chief Compliance Officer, along with holding a variety of operational and corporate strategy roles. He has also formerly served as Executive Vice President, General Counsel for Infinity Pharmaceuticals, Inc., and as Senior Vice President, Acting Chief Operating Officer and General Counsel for Salix Pharmaceuticals, where he remained as General Manager to help finalize the integration of the company's $14 billion acquisition by Valeant Pharmaceuticals in April 2015. He is currently a member of the board of directors of Ardelyx, Inc. (Nasdaq:ARDX). Mr. Bertrand received a J.D. from the University of Wisconsin and a B.S. in biology from Wayne State University.
What is the salary of William Bertrand?
As the Chief Operating Officer of Adaptimmune Therapeutics Plc, the total compensation of William Bertrand at Adaptimmune Therapeutics Plc is 1,369,510$. There are 2 executives at Adaptimmune Therapeutics Plc getting paid more, with James Noble having the highest compensation of 2,821,740$.
How old is William Bertrand?
William Bertrand is 55, he's been the Chief Operating Officer of Adaptimmune Therapeutics Plc since 2017. There are 7 older and 10 younger executives at Adaptimmune Therapeutics Plc. The oldest executive at Adaptimmune Therapeutics Plc is Lawrence Alleva, 70, who is the Non-Executive Independent Director.
What's William Bertrand's mailing address?
William's mailing address filed with the SEC is C/O ARDELYX, INC., 400 FIFTH AVENUE, SUITE 210, WALTHAM, MA, 02451.
Insiders trading at Adaptimmune Therapeutics Plc
Over the last 9 years, insiders at Adaptimmune Therapeutics Plc have traded over 40,532,026$ worth of Adaptimmune Therapeutics Plc stock and bought 384,338,252 units worth 527,131,726$ . The most active insiders traders include Forest Baskett、Scott D Sandell、Anthony A. Jr. Florence. On average, Adaptimmune Therapeutics Plc executives and independent directors trade stock every 20 days with the average trade being worth of 2,827,332$. The most recent stock trade was executed by Cintia Piccina on 18 June 2024, trading 24,531 units of ADAP stock currently worth 22,814$.
What does Adaptimmune Therapeutics Plc do?
adaptimmune llc is a multinational, clinical-stage biopharmaceutical company focused on developing novel immunotherapies using its proprietary t-cell receptor platform that has the potential to transform the treatment of cancer. established in 2008, the company has grown from being privately held to one of the most successful biopharmaceutical initial public offerings (ipo) in 2015. with u.s. operations based in philadelphia, pa, adaptimmune is a company founded on strong science that has led to a robust pipeline of immuno-oncology product candidates, a growing research & development platform and ongoing plans for expansion. for more information about adaptimmune, please visit www.adaptimmune.com. if interested in joining our fast growing team, click on the careers tab of this page.
What does Adaptimmune Therapeutics Plc's logo look like?
Complete history of Mr. Bertrand stock trades at Adaptimmune Therapeutics Plc、Ardelyx Inc、Infinity Pharmaceuticals
Adaptimmune Therapeutics Plc executives and stock owners
Adaptimmune Therapeutics Plc executives and other stock owners filed with the SEC include:
-
James Noble,
Non-Executive Director -
Adrian Rawcliffe,
Chief Executive Officer, Director -
William Bertrand,
Chief Operating Officer -
Helen Tayton-Martin,
Chief Business Officer -
Adrian G. Rawcliffe,
CEO, Principal Accounting Officer & Director -
Dr. Helen Katrina Tayton-Martin MBA, Ph.D.,
Co-Founder & Chief Bus. Officer -
William C. Bertrand Jr.,
Chief Operating Officer -
Gavin Hilary James Wood BA (Hons), ACA,
Chief Financial Officer -
David Mott,
Non-Executive Independent Chairman of the Board -
Tal Zvi Zaks,
Non-Executive Independent Director -
Elliott Sigal,
Non-Executive Independent Director -
John Furey,
Non-Executive Independent Director -
Barbara Duncan,
Non-Executive Independent Director -
Ali Behbahani,
Non-Executive Independent Director -
Lawrence Alleva,
Non-Executive Independent Director -
John Lunger,
Chief Patient Supply Officer -
Elliot Norry,
Senior Vice President, Chief Medical Officer -
Gavin Wood,
Chief Financial Officer -
Dr. Arundathy Nirmalini Pandite M.B.A., M.D.,
Sr. VP of Clinical Devel. -
Dr. Rafael G. Amado,
Pres of R&D -
Sébastien Desprez,
VP of Communications & Corp. Affairs -
Margaret Henry,
Head of PR & Company Sec. -
Dr. Juli P. Miller Ph.D.,
VP of Investor Relations -
Ravi Viswanathan,
10% owner -
Scott D Sandell,
10% owner -
Gwendolyn Knowlton Binder S...,
EVP, Adaptimmune LLC -
Giles Francis Bertram Kerr,
Director -
Jonathan Kenneth Charles Kn...,
Director -
Forest Baskett,
10% owner -
Ian Michael Laing,
Director -
Rafael Amado,
President, R&D -
Peter A. Thompson,
Director -
Peter W. Sonsini,
10% owner -
Patrick J Kerins,
10% owner -
Anthony A. Jr. Florence,
10% owner -
M James Barrett,
10% owner -
Enterprise Associates 14, L...,
-
Advisors Llc Orbi Med Capit...,
-
Peter J Barris,
10% owner -
Advisors Llc Orbi Med Capit...,
-
Kristen Hege,
Director -
Priti Hegde,
Director -
Andrew R Allen,
Director -
Cintia Piccina,
Chief Commercial Officer -
Joanna Elizabeth Brewer,
Chief Scientific Officer -
Garry E Menzel,
Director